Anti-CYP2D6 antibody [EPR17868]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(3 Publications)
Rabbit Recombinant Monoclonal CYP2D6 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 3 publications.
View Alternative Names
CYP2DL1, CYP2D6, Cytochrome P450 2D6, CYPIID6, Cholesterol 25-hydroxylase, Cytochrome P450-DB1, Debrisoquine 4-hydroxylase
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed HT-29 (Human colorectal adenocarcinoma cells) cells labeling CYP2D6 with ab185625 at 1/300 dilution (red) compared with a rabbit monoclonal IgG isotype control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized HT-29 (Human colorectal adenocarcinoma cells) cells labeling CYP2D6 with ab185625 at 1/1000 dilution followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/400 dilution (green). Cytoplasmic staining on HT-29 cell line is observed. The nuclear counter stain is DAPI (blue). Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/500 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
The negative controls are as follows :
-ve control 1 : ab185625 at 1/1000 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
-ve control 2 : ab7291 (anti-Tubulin mouse mAb) at 1/500 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/400 dilution.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling CYP2D6 with ab185625 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human liver is observed. Counter stained with Hematoxylin.
Negative control : Used PBS instead of primary antibody secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling CYP2D6 with ab185625 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human kidney is observed. Counter stained with Hematoxylin.
Negative control : Used PBS instead of primary antibody secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Immunohistochemical analysis of paraffin-embedded Human hepatocellular carcinoma tissue labeling CYP2D6 with ab185625 at 1/500 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) secondary antibody at 1/500 dilution. Cytoplasmic staining on Human hepatocellular carcinoma is observed. Counter stained with Hematoxylin.
Negative control : Used PBS instead of primary antibody secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB
Supplier Data
Western blot - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-CYP2D6 antibody [EPR17868] (ab185625) at 1/1000 dilution
All lanes:
HT-29 (Human colorectal adenocarcinoma cells) whole cell lysate at 10 µg
Secondary
All lanes:
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 37 kDa,56 kDa
Observed band size: 55 kDa
false
- WB
Supplier Data
Western blot - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-CYP2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution
Lane 1:
HeLa (Human epithelial cells from cervix adenocarcinoma) whole cell lysate at 20 µg
Lane 2:
K562 (Human chronic myelogenous leukemia cells from bone marrow) whole cell lysate at 20 µg
Lane 3:
HepG2 (Human liver hepatocellular carcinoma) whole cell lysate at 20 µg
Secondary
All lanes:
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 56 kDa
Observed band size: 55 kDa
false
- WB
Supplier Data
Western blot - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Blocking/Dilution buffer : 5% NFDM/TBST.
Full-length CYP2D6 293T overexpressed lysates contain GFP tagged-aa1-497.
All lanes:
Western blot - Anti-CYP2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution
Lane 1:
Full-length CYP2D6 transfected 293T cell lysate at 10 µg
Lane 2:
Non-transfected 293T lysate at 10 µg
Secondary
All lanes:
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 56 kDa
Observed band size: 81 kDa
false
- WB
Supplier Data
Western blot - Anti-CYP2D6 antibody [EPR17868] (AB185625)
Blocking/Dilution buffer : 5% NFDM/TBST.
Based on the sequence analysis, ab185625 recognizes two isoforms with the predicted MWs of 55kDa and 50kDa respectively.
All lanes:
Western blot - Anti-CYP2D6 antibody [EPR17868] (ab185625) at 1/10000 dilution
All lanes:
Human fetal liver tissue lysate at 20 µg
Secondary
All lanes:
Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 56 kDa
Observed band size: 50 kDa,55 kDa
false
Related conjugates and formulations (3)
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-CYP2D6 antibody [EPR17868]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-CYP2D6 antibody [EPR17868]
-
Anti-CYP2D6 antibody [EPR17868] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Enzymes related to drug metabolism perform essential roles in the detoxification of foreign chemicals. CYP2D6 is notably part of the microsomal enzyme complex in the liver. It facilitates the transformation of lipophilic compounds into more water-soluble metabolites rendering them easier for the body to excrete. This enzyme affects the bioavailability and efficacy of many medications such as antidepressants antipsychotics and beta-blockers. Its role is integral in the activation of certain prodrugs converting them into their active pharmacological forms.
Pathways
CYP2D6 functions significantly in drug metabolism and clearance pathways. It takes part in the Phase I metabolism pathway where it initiates the oxidation of drugs setting the stage for further modifications. It interacts closely with other CYP enzymes like CYP3A4 which sometimes share substrates and inhibitors affecting their metabolic activities. CYP2D6's interaction with these pathways emphasizes its involvement in the intricate network of enzyme-mediated drug handling in the body.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in immunology 13:837991 PubMed35359973
2022
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 294:10336-10348 PubMed31113867
2019
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 6:6332 PubMed25757189
2015
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com